Condition: Cervical Cancer · Sponsor: Kortuc, Inc.
This is a seamless Phase 1/2 study consisting of two components. Phase 1 component is a dose-escalation, single arm, open label study in 10 patients to evaluate the safety and tolerability of KRC 01. Phase 2 component is a randomized, open label, controlled, multi-center study in 60 patients to evaluate the preliminary antitumor effect of KRC-01 in combination with CRT.
This description comes directly from the study's public registry record.
Martine Francis · 13013438894 · martine@mafinc.com
Minako Koga · 2026156004 · mkoga@kmphc.com
Always discuss trial participation with your own doctor first.
| Site 2 | Chandigarh, India | Not Yet Recruiting |
| Site 5 | Bangkok, Bangkok, Thailand | Recruiting |
| Site 4 | Chiang Mai, Thailand | Recruiting |
| Site 3 | Manchester, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05570422